Suicidality
Suicidality covers the spectrum of suicidal thoughts, plans and behaviours, and it contributes to more than 727,000 deaths worldwide each year. The strongest evidence for rapidly reducing suicidal thinking is for ketamine and esketamine, and esketamine carries a specific regulatory approval. But even there, a reduction in suicide itself has not been proven, and classic psychedelics remain unproven for suicidality and can carry real risks for people in crisis. This is a research summary, not medical advice.
How are psychedelics being studied in relation to suicidal thinking? Suicidal thinking can occur across many mental health conditions and needs urgent, careful care. Research interest centres on ketamine and esketamine, which can reduce suicidal thoughts within hours and are studied specifically for depression with suicidal ideation, offering a speed that standard antidepressants cannot match. Psilocybin trials also track suicidal thinking as part of their depression outcomes. Because of the risks involved, these studies use close monitoring and supportive care, delivered in supervised settings. The evidence points to rapid short-term reductions, but how to sustain benefit and prevent relapse remains an open and serious question. Blossom tracks the trials and papers in this area so you can follow the evidence. This is research information, not crisis support; if you need help now, contact local emergency services.
Data updated
Key Insights
- 1
The strongest evidence for rapidly reducing suicidal ideation is for ketamine and esketamine, which can lower suicidal thoughts within hours. Classic psychedelics are far less studied for this and are not proven treatments for suicidality.
- 2
Esketamine (Spravato) is FDA-approved (2020) for depressive symptoms in adults with major depression who have acute suicidal ideation or behaviour, but the label itself states that its effectiveness in preventing suicide or reducing suicidal ideation has not been demonstrated.
- 3
Across rigorous trials these drugs reliably improve depression yet repeatedly fail to beat placebo or an active control on suicidality-specific measures, so "reduces ideation fast" is not the same as "prevents suicide".
- 4
Classic psychedelics show only preliminary, mostly uncontrolled or secondary-outcome signals for suicidality, and some trials report more suicidal ideation on dosing days, so the risks in vulnerable people are real.
- 5
Most psychedelic trials exclude people at acute suicide risk, so the evidence base says little about the people most in need. Any concern about suicide should go through emergency and specialist care, not self-experimentation.
By the numbers
- 94
- Trials tracked
- 241
- Papers tracked
- 10,988
- Trial participants
as of June 2026
as of June 2026
as of June 2026
Questions & Answers
The questions readers most often ask about Suicidality, answered with the data Blossom tracks.
Can ketamine reduce suicidal thoughts?
Trials report that ketamine and esketamine can reduce suicidal thinking within hours, which is why they are studied for depression with suicidal ideation. This is research information, not crisis support. Blossom tracks the trials.
Where can I get help in a crisis?
If you are in crisis, contact local emergency services or a suicide helpline now. Blossom provides research information, not crisis support.
What is Suicidality?
Suicidality is an umbrella term for a spectrum that runs from passive thoughts that life is not worth living, through active suicidal ideation, to plans, attempts and death by suicide. It is one of the most serious outcomes in mental health: the World Health Organization estimates that more than 727,000 people die by suicide each year, and that suicide is the third leading cause of death among 15 to 29 year-olds[1]. Suicidality is not a diagnosis in itself; it most often accompanies depression, but also bipolar disorder, PTSD, substance use disorders, borderline personality disorder and acute crises.
This page focuses on what the research on psychedelic and rapid-acting compounds does, and does not, show about reducing suicidal thoughts and behaviour. It is a research summary, not medical advice or a treatment recommendation, and it is deliberately cautious. The honest headline is that some of these drugs can lower suicidal ideation quickly, but lowering ideation in a trial is not the same as preventing suicide, and the people at highest risk are usually excluded from the studies. If you are struggling with thoughts of suicide, please use the crisis resources at the top of the research report below and speak to a qualified professional.
Current Treatments
The foundations of suicide care are not drugs. They are timely access to help, collaborative safety planning, restricting access to lethal means, and treating the underlying condition. Structured psychotherapies have the best evidence for reducing suicidal behaviour: cognitive behavioural therapy for suicide prevention and dialectical behaviour therapy both reduce repeat attempts. For specific diagnoses, two older medicines stand out for actually lowering suicide risk over time: lithium in mood disorders and clozapine in schizophrenia. For severe or psychotic depression, electroconvulsive therapy (ECT) acts quickly.
The gap these older tools leave is speed. Standard antidepressants take weeks to work, and in young people they carry a boxed warning for a possible early increase in suicidal thinking. That lag is dangerous precisely when risk is highest, in the days and weeks around a crisis or a hospital discharge. The appeal of rapid-acting agents such as ketamine and esketamine is that they can reduce suicidal ideation within hours rather than weeks, buying time for slower treatments and support to take hold. Whether that rapid drop in ideation translates into fewer deaths is the central, still-unresolved question of this whole field.
This report summarises what Blossom’s database shows about psychedelic and rapid-acting treatments for suicidality, and, just as importantly, what it does not show. The short version: the strongest evidence is that ketamine and esketamine can reduce suicidal thoughts quickly, and esketamine has a regulatory approval that names suicidality. But reducing ideation in a trial is not the same as preventing suicide, the people at highest risk are usually excluded from the studies, and classic psychedelics remain unproven and carry real risks for people in crisis. Caution, not enthusiasm, is the honest posture here.
If you are in crisis, read this first
If you are having thoughts of suicide, please reach out for help now. Contact your local emergency services, or a crisis line: in the US you can call or text 988 (the Suicide and Crisis Lifeline); in the UK and Ireland you can call Samaritans on 116 123; and findahelpline.com lists free, confidential services in most countries. You are not alone, and help is available. Nothing on this page is a treatment recommendation, and none of the compounds discussed should be used for a suicidal crisis outside professional medical care.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Of the treatments discussed, only ketamine (off-label) and esketamine are in routine clinical use, and both are given under medical supervision; the classic psychedelics are investigational. Decisions about treating depression and suicide risk belong with a qualified clinician.
On the numbers: Blossom currently tracks 246 papers and 94 trials tagged to this topic, and those counts appear on this page. The tag is leaky. A large share of the records are about depression broadly, or carry suicidality only as a secondary or safety outcome, including studies in OCD, PTSD, substance use and cost-of-care analyses. So read the counts as database coverage, not as a clean tally of suicidality-specific research, and note that some landmark single-infusion ketamine trials are not in our set, so the picture below is conservative rather than complete. The large majority of the records we do track involve ketamine or esketamine rather than classic psychedelics, which itself tells you where the real evidence sits.
What suicidality is, and why speed matters
Suicidality runs from fleeting thoughts that life is not worth living to active ideation, plans, attempts and death. The WHO estimates more than 727,000 suicide deaths a year worldwide[1]. It is rarely a condition in isolation; it travels with depression, bipolar disorder, PTSD, substance use and acute crises. The treatments with the best evidence for actually lowering suicide risk are not new and not psychedelic: psychotherapies such as CBT for suicide prevention and dialectical behaviour therapy, lithium in mood disorders, clozapine in schizophrenia, restricting access to lethal means, and timely human support.
What those tools lack is speed. Standard antidepressants take weeks, and in young people carry a warning about a possible early increase in suicidal thinking. That delay is most dangerous exactly when risk peaks. The entire rationale for ketamine-class drugs in this setting is that they can lower suicidal ideation within hours, potentially bridging the dangerous gap until slower treatments and support take effect. Holding that promise and its limits in view at the same time is the work of this page.
Ketamine: fast, real, and short-lived
Intravenous racemic ketamine has the most convincing rapid-acting signal for suicidal ideation. A midazolam-controlled trial in treatment-resistant depression with prominent suicidal ideation[2] and real-world infusion data[3] both show suicidal thoughts dropping within hours to days. Because no company owns the molecule, it is cheap and widely used off-label, but for the same reason access, dosing and quality are inconsistent across clinics.
The weakness is durability. The benefit fades within days to weeks, so a dramatic acute response becomes an open-ended maintenance question. Research is testing how to extend it, for instance adding low-dose buprenorphine after an infusion produced greater reduction in suicidal ideation than placebo, with no change in depression scores[4], a hint that the antisuicidal and antidepressant effects may be partly separable. But ketamine is a controlled drug with genuine abuse potential, illustrated by a case of addiction after a single infusion given for acute suicidality[5], and its evidence in acutely suicidal adolescents is weak, with a paediatric ED pilot showing no significant ideation benefit over control[6].
Esketamine: an approval that names suicidality, with an asterisk
Esketamine (Spravato) is the only compound here whose label names suicidality. In 2020 the FDA approved it for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour[7], on the back of the ASPIRE I and ASPIRE II trials[8], which showed rapid improvement in depression within 24 hours added to comprehensive standard care. For a field starved of regulatory validation, that mattered.
The asterisk is large and comes straight from the regulator: the label states that effectiveness in preventing suicide, or in reducing suicidal ideation or behaviour, has not been demonstrated. The trial data agree. A 2025 PRISMA meta-analysis found the suicidality effect was not significant at any time point, while the depression effect was modest (effect size roughly 0.15 to 0.23)[9]; a 2026 relapse-prevention trial found no group difference on the Columbia Suicide Severity Rating Scale[10]; and in adolescents esketamine improved depression but not suicidality severity specifically[11]. The pattern is consistent: depression improves, the suicidality-specific needle does not reliably move against control.
Classic psychedelics: promising elsewhere, not here
The classic psychedelics, where most of the public excitement lives, are the weakest part of the suicidality evidence. For psilocybin, the most direct study is a 2026 open-label trial of a single dose for chronic suicidal ideation (n=20) reporting large, sustained within-group reductions and no serious adverse events[12], but with no control group and only twenty participants it is hypothesis-generating, and the authors say so. Set against it is a safety signal: in a 2026 treatment-resistant depression RCT, psilocybin missed its primary endpoint and was associated with more suicidal ideation on dosing days[13].
A broader review found serious adverse events, including suicidal behaviour, worsening depression and psychosis, in around 4% of participants with pre-existing neuropsychiatric disorders[14]. Ayahuasca is weaker still, limited to small qualitative reports[15] with no controlled evidence, and it carries real interaction and destabilisation risks in unsupervised settings. Population surveys sometimes report associations between psychedelic use and lower impulsivity or distress, for example a naturalistic survey of 2,510 people[16], but these are cross-sectional, self-reported and heavily confounded, and cannot establish that psychedelics reduce suicide. Crucially, most of these trials exclude people at acute suicide risk, so they say little about the population this page concerns.
The gap between reducing ideation and preventing suicide
This is the single most important idea on the page. A drug can lower a suicidal-ideation score in a trial without having been shown to save lives, because suicide is rare enough that no trial so far has been large or long enough to measure deaths, because rated ideation and actual behaviour are not the same thing, and because effects that fade within weeks may not cover the period of risk. That is why the esketamine label is careful, and why every claim here separates "reduced suicidal thinking in a study" from "prevents suicide". Treat any source that blurs the two with suspicion.
Safety, and who is left out
The safety picture is genuinely mixed and should be presented as such. Post-marketing analyses of esketamine disagree: a European pharmacovigilance analysis flagged a potential increase in suicide risk versus older antidepressants[17], while a near-five-year US real-world analysis found no new safety signals[18]. Ketamine carries abuse potential; classic psychedelics can worsen ideation acutely in vulnerable people. And running through all of it is a selection problem: the people at highest risk, those who are actively suicidal, are routinely excluded from the trials, so the evidence is strongest for exactly the people who need it least and thinnest for those who need it most.
Reading this honestly
So where does suicidality sit? It is a setting where rapid-acting drugs can do something real and fast, lower suicidal thoughts within hours, which is not nothing when the alternative is weeks of waiting. But the honest reading refuses two temptations: the breathless one that treats a fast drop in ideation as a cure for suicide, and the dismissive one that ignores a genuine, regulator-recognised tool. The defensible position is narrow and cautious: ketamine and esketamine can help reduce acute suicidal ideation under medical supervision, suicide prevention itself remains unproven for every compound here, classic psychedelics are not a treatment for suicidality and may be hazardous in crisis, and none of this substitutes for human support, safety planning and timely professional care. If you are struggling, please use the crisis resources at the top of this report.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Suicidality.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ketamine Intravenous racemic ketamine repeatedly reduces suicidal ideation within hours in depression, including in midazolam-controlled trials, but the effect is transient (days to weeks), the suicide-prevention question is unanswered, and quality varies across off-label clinics. | Medium | Moderate | Moderate |
| Esketamine FDA-approved (2020) for depressive symptoms in MDD with acute suicidal ideation or behaviour on the strength of ASPIRE I/II. But those trials and a 2025 meta-analysis found no significant benefit over control on suicidality-specific endpoints, and the label states suicide prevention has not been demonstrated. | Small | High | Moderate |
| Psilocybin Only preliminary, mostly uncontrolled signals for suicidality (one small open-label trial). A 2026 treatment-resistant depression RCT was negative on its primary endpoint and reported more suicidal ideation on dosing days, so this is not an established treatment and may carry acute risk. | Small | Very Low | Low |
| Ayahuasca Limited to small, mostly observational or qualitative reports. There is no controlled evidence that ayahuasca reduces suicidality, and ceremonial use is unsupervised and unregulated. | Small | Very Low | Low |
Ketamine and Suicidality
Intravenous racemic ketamine is the most studied rapid-acting option for suicidal ideation. A midazolam-controlled trial in treatment-resistant depression with prominent suicidal ideation[1] and real-world IV ketamine data[2] both show suicidal thoughts falling within hours to days of a single sub-anaesthetic infusion. It is cheaper than esketamine and widely used off-label, though access and quality vary because no company owns the molecule.
The honest counterweight is durability and risk. The antisuicidal effect is rapid but short-lived, which is why researchers are testing ways to extend it: a 2026 trial found that adding low-dose buprenorphine after a ketamine infusion produced greater reduction in suicidal ideation than placebo (mean change minus 11.6 versus minus 6.3 on the Scale for Suicide Ideation)[3], while depression scores did not differ. Ketamine is also a controlled drug with abuse potential: a 2026 case describes ketamine addiction following a single sub-anaesthetic infusion given for acute suicidality[4]. In acutely suicidal young people the signal is weaker still: a paediatric emergency-department pilot found no significant difference in ideation severity versus control, though fewer ketamine patients were hospitalised[5].
Esketamine and Suicidality
Esketamine (the S-enantiomer of ketamine, sold as Spravato) is the only compound here with a regulatory approval that names suicidality. In 2020 the FDA approved it for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour[1], based on the ASPIRE I and ASPIRE II trials[2], which showed a rapid improvement in depression within 24 hours when added to standard care.
The crucial caveat is in the approval itself: the FDA label states that the effectiveness of Spravato in preventing suicide, or in reducing suicidal ideation or behaviour, has not been demonstrated. That is borne out by the wider evidence. A 2025 meta-analysis found the effect on suicidality was not significant at any time point[3], and a 2026 relapse-prevention trial similarly found no group difference on the Columbia Suicide Severity Rating Scale[4]. In adolescents, esketamine improved depression but not suicidality severity specifically[5]. It improves mood quickly; it is not a proven anti-suicide drug.
Psilocybin and Suicidality
The psilocybin evidence for suicidality specifically is thin and must be read with care. The most direct signal is a 2026 open-label trial of a single dose for chronic suicidal ideation (n=20), which reported large within-group reductions sustained to twelve weeks with no serious adverse events[1]. But it had no control arm and only twenty participants, and the authors themselves frame it as preliminary support for larger randomised trials.
The safety counterpoint is important. In a 2026 randomised trial in treatment-resistant depression, psilocybin missed its primary endpoint and was linked to higher reports of suicidal ideation on dosing days (around 4% versus 1 to 2% in comparators)[2], and a systematic review found serious adverse events including suicidal behaviour and worsening depression in roughly 4% of participants with pre-existing neuropsychiatric disorders[3]. Most psilocybin trials exclude people at acute suicide risk, so there is little basis for using it in exactly the population this page is about.
Ayahuasca and Suicidality
Ayahuasca is sometimes discussed in connection with suicidality because of self-reported emotional release in ceremonial settings, but the tracked evidence is the weakest of any compound here. It amounts to small observational and qualitative reports (for example, in-depth interviews with nine people)[1] that are hypothesis-generating at best. There is no controlled trial showing ayahuasca reduces suicidal ideation or behaviour.
Ceremonial ayahuasca is also unsupervised, unregulated and pharmacologically active in ways that matter for vulnerable people: it interacts dangerously with several antidepressants (it contains monoamine oxidase inhibitors) and can provoke intense, destabilising psychological experiences. For someone in crisis, that is a real hazard, not a therapy.
Clinical Outlook
The near-term story is about closing the gap between two facts that sit uncomfortably together: ketamine-class drugs can drop suicidal ideation within hours, yet no psychedelic or rapid-acting agent has been shown to prevent suicide. The active research questions follow from that. How do you make a rapid effect last, with maintenance dosing, augmentation such as buprenorphine after ketamine[1], or follow-on psychotherapy such as CBT after esketamine[2]? And can a trial ever be powered and ethical enough to measure suicide deaths rather than ideation scores?
Expect the centre of gravity to stay with ketamine and esketamine, where the regulatory and safety infrastructure already exists, rather than with classic psychedelics, which remain investigational and largely untested in acutely suicidal people. The most useful advances may be unglamorous: better real-world safety monitoring, clearer guidance on which patients benefit, and integration of rapid-acting medication into crisis pathways alongside safety planning and means restriction, rather than a search for a single anti-suicide pill.
Industrial Landscape
The commercial landscape for suicidality is narrow and centred on one product. Johnson & Johnson, through its Janssen division, owns esketamine (Spravato) and secured the 2020 FDA indication for major depression with acute suicidal ideation or behaviour[1], the only approval in this space that names suicidality. Its value proposition is speed and a certified-clinic delivery model (a REMS programme), and much of the recent literature is post-approval real-world and health-economics work rather than new efficacy trials.
Around that sit academic and pharmacovigilance groups whose findings do not always flatter the product, and which a balanced page should report. Post-marketing safety analyses disagree: a 2025 EudraVigilance disproportionality analysis flagged a potential increase in suicide risk with esketamine versus fluoxetine and venlafaxine[2], whereas a near-five-year US real-world analysis found no new safety signals[3]. Uncontrolled cohorts add nuance, for example esketamine being associated with reduced self-harm in treatment-resistant depression with and without borderline personality disorder[4]. These tensions are unresolved and should be held together, not resolved by dropping the inconvenient half.
Quick Indicators
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Instituto do Cérebro, Universidade Federal do Rio Grande do Norte
The Instituto do Cérebro (Brain Institute, ICe) is an academic research institute of the Federal University of Rio Grande do Norte (UFRN) in Natal, Brazil, focused on neuroscience research, education and public outreach. It hosts the postgraduate Program in Neurosciences (PGNeuro) and supports related research groups and events.
University Medical Center Groningen
The University Medical Center Groningen (UMCG) is the academic hospital affiliated with the University of Groningen, providing tertiary and specialized patient care while conducting medical research and education. It is one of the largest university hospitals in the Netherlands and serves as the main academic medical center for the northern Netherlands.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS as a commercial spinout to carry MAPS MDMA research through late-stage trials and regulatory approval. After two Phase 3 trials and an NDA filing, FDA issued a Complete Response Letter in August 2024 and requested an additional Phase 3 trial before approval. The company subsequently restructured and rebranded, while the public Lykos web presence continues to describe the organisation as pursuing FDA approval for MDMA-assisted therapy. As of the June 2026 review, no public company announcement of a new pivotal trial start or NDA resubmission date was found. VA/DoD-backed MDMA/PTSD research is proceeding in the broader field, but it should not be treated as direct support for Resilient/Lykos NDA resubmission unless linked by company or FDA evidence.
MAPS
MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Imperial College London
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Charité – Universitätsmedizin Berlin
The MIND Foundation partnered with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals. Charité is affiliated with Humboldt University and Free University Berlin. This partnership sees researchers at the hospital carrying out clinical studies with psilocybin in patients with treatment-resistant depression. Studies also take place concurrently at the Central Institute for Mental Health Mannheim.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
John Kelly
Associate Professor / Consultant General Psychiatrist at Trinity College Dublin
John R. Kelly is a leading academic psychiatrist in Ireland whose work has helped shape modern psychedelic psychiatry, including psilocybin research across depression, service-user attitudes, and transdiagnostic treatment frameworks.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Connected Evidence
The latest clinical data and verified academic findings associated with Suicidality.